Trexquant Investment LP Has $19.82 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Trexquant Investment LP grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 39.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 595,146 shares of the biotechnology company’s stock after purchasing an additional 167,907 shares during the quarter. Trexquant Investment LP owned about 0.21% of Exelixis worth $19,818,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in EXEL. USA Financial Formulas acquired a new position in Exelixis during the fourth quarter worth $32,000. Principal Securities Inc. grew its position in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC acquired a new position in shares of Exelixis during the 4th quarter worth about $39,000. UMB Bank n.a. raised its holdings in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 553 shares during the period. Finally, Crowley Wealth Management Inc. acquired a new stake in Exelixis in the 4th quarter valued at about $50,000. Institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Citigroup upped their price objective on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Wells Fargo & Company downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target for the company. in a report on Monday, February 24th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Stephens reissued an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their target price on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.59.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 140,343 shares of company stock worth $5,177,234. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

Exelixis stock opened at $36.92 on Tuesday. The stock has a fifty day moving average of $35.72 and a 200-day moving average of $33.39. The stock has a market capitalization of $10.33 billion, a P/E ratio of 20.86, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.